Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurologic disorder characterized by muscular weakness and fasciculations, progressive atrophy, and abnormal muscle stretch reflexes. It is the most common sporadic form of the motor neuron diseases, although 5%-10% of cases are genetically transmitted (1). Pathological features of ALS include loss of motor neurons in the spinal cord, brainstem, and primary motor cortex, along with demyelination or sclerosis of long motor tracts, with occasional intranuclear inclusions, proliferation of neurofilaments, and ubiquitinpositive skeins in cortical neurons (2). The cause(s) and cure of ALS are not yet known, although numerous theories of etiopathogenesis have been advanced since the original clinicopathologic description of the illness by Charcot and Joffroy in 1869 (3, 4).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Festoff BW. Amyotrophic lateral sclerosis: the syndrome, its pathophysiology and approach to treatment. In: Davidoff RA, ed. Handbook of the spinal cord; vols 4, 5. New York: Marcel Dekker, 1987:607–64.
Wightman G, Anderson VER, Martin J, et al. Hippocampal and neocortical ubiquitin-immunoreactive inclusions in amyotrophic lateral sclerosis with dementia. Neurosci Lett 1992;139:269–74.
Charcot JM, Joffroy A. Deux cas d’atrophie musculaire progressive avec lesions de la moelle epiniere. Arch Physiol 1869;2:354,629,744.
Appel SH. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism and Alzheimer’s disease. Ann Neurol 1981;10:499–505.
Siddique T, Figlewicz DA, Pericak-Vance MA, et al. Linkage of a gene familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic-locus heterogeneity. N Engl J Med 1991;324:1381–4.
Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59–62.
Stálberg E. Recent progress in ALS neurophysiology. In: Tsubaki T, Yase Y, eds. Amyotrophic lateral sclerosis: recent advances in research and treatment. Amsterdam: Excerpta Medica, 1988:155–60.
Rodriguez-Tebar A, Dechant G, Barde YA. Neurotrophins-structural relatedness and receptor interactions. Philos Trans R Soc Lond [Biol] 1991; 331:255–8.
McMorris FA, Smith TM, DeSalvo S, Furlanetto RW. Insulin-like growth factor-I/somatomedin C: a potent inducer of oligodendrocyte development. Proc Natl Acad Sci USA 1986;83:822–6.
Bondy CA. Transient IGF-I gene expression during the maturation of functionally related central projection neurons. J Neurosci 1991;11:3442–55.
Caroni P, Grandes P. Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin-like growth factors. J Cell Biol 1990;110:1307–17.
Caroni P. Activity-sensitive signaling by muscle-derived insulin-like growth factors in the developing and regenerating neuromuscular system. Ann NY Acad Sci 1992;692:209–22.
Hamo K, Rissanen A, Palo J. Glucose tolerance in amyotrophic lateral sclerosis. Acta Neurol Scand 1984;70:451–5.
Reyes ET, Perurena OH, Festoff BW, Popiela H. Role of insulin receptors and insulin insensitivity in amyotrophic lateral sclerosis and related diseases. In: Research progress in motor neuron disease. London: Pitman, 1984:26375.
Perurena OH, Festoff BW. Reduction in insulin receptors in ALS correlates with reduced insulin severity. Neurology 1987;37:1375–83.
Reyes ET, Perurena OH, Festoff BW, Jorgensen R, Moore WV. Insulin resistance in amyotrophic lateral sclerosis. J Neurol Sci 1984;63:317–24.
Festoff BW, Melmed S, Smith RA. Therapeutic trial of recombinant human growth hormone in amyotrophic lateral sclerosis. In: Serratrice G, Pellissier J-F, Desnuelle C, Pouget J, eds. Advances in neuromuscular diseases. Paris: Expansion Scientifique Française, 1989:117–26.
Hubbard RW, Will AD, Peterson GW, Sanchez A, Gillan WW, Tan SA. Elevated plasma glucagon in amyotrophic lateral sclerosis. Neurology 1992; 42:1532–4.
Smith RA, Melmed S, Sherman B, Frane J, Munstat TL, Festoff BW. Recombinant growth hormone treatment of amyotrophic lateral sclerosis. Muscle Nerve 1993;16:624–33.
Pradas J, Finison L, Andres PL, Thornell B, Hollander D, Munsat TL. The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials. Neurology 1993;43:751–5.
Cox DR. Regression models and life-tables (with discussion). JR Stat Soc 1972;B34:187–220.
Braunstein GD, Revicky AL. Serum insulin-like growth factor-I levels in ALS. J Neurol Neurosurg Psych 1987;50:792–4.
Rao U, Shetty KR, Mattson DE, Rudman IW, Rudman D. Prevalence of low plasma IGF-I in poliomyelitis survivors. J Am Geriatr Soc 1993;41:697–702.
Caroni P, Becker M. The downregulation of growth-associated proteins in motoneurons at the onset of synapse elimination is controlled by muscle activity and IGF-I. J Neurosci 1992;12:3849–61.
Leong SR, Baxter RC, Camerato T, Dai J, Wood WI. Structure and functional expression of the acid-labile subunit of the insulin-like growth factor binding protein complex. Mol Endocrinol 1992;6:870–6.
Baxter RC, Martin JL. Binding proteins for insulin-like growth factors: structure, regulation, and function. Prog Growth Factor Res 1989;1:49–68.
Stong D, Raskin R. Effects of multiple subcutaneous doses of rhIGF-I on total and free IGF-I levels and blood glucose in humans. In: Raizada MK, LeRoith D, eds. The role of insulin-like growth factors in the nervous system. Ann New York Acad Sci 1993;692:317–20.
Hossenlopp P, Seurin D, Segovia-Quinson B, Hardouin S, Binoux M. Analysis of serum insulin-like growth factor binding proteins using Western blotting: use of the method for titration of the binding proteins and competitive binding studies. Anal Biochem 1986;154:138–43.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this paper
Cite this paper
Festoff, B.W., Yang, S.X., Stong, D. (1995). Strategies for the Use of Recombinant Human Growth Hormone and Insulin-Like Growth Factor I in Amyotrophic Lateral Sclerosis. In: Blackman, M.R., Roth, J., Harman, S.M., Shapiro, J.R. (eds) GHRH, GH, and IGF-I. Serono Symposia USA. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-0807-5_11
Download citation
DOI: https://doi.org/10.1007/978-1-4612-0807-5_11
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-6908-3
Online ISBN: 978-1-4612-0807-5
eBook Packages: Springer Book Archive